Do GLP-1 Drugs Pose a Risk to Lung Transplant Recipients?
People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a small, single-center cohort study suggested. In a retrospective review of 301 consecutive lung transplants, the 34 lung recipients taking a GLP-1 drug for diabetes or obesity early in their post-transplant course had 15.19-fold (95% CI 2.08-23.55, P<0.05) […]
Novel CAR-T for Glioblastoma Induced ‘Dramatic’ Responses in Early Trial
A new approach to chimeric antigen receptor (CAR) T-cell therapy showed promise in treating recurrent glioblastoma, according to a small phase I study. In the first-in-human trial, three patients with recurrent glioblastoma who were treated with CARv3-TEAM-E T cells experienced “dramatic and rapid” tumor regression within days of receiving a single intraventricular infusion, reported Marcela […]
Apalutamide Makes Its Case in Biochemically Recurrent Nonmetastatic Prostate Cancer
A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients with high-risk, biochemically recurrent prostate cancer, according to interim results from a phase III trial. In the three-arm PRESTO study, adding either apalutamide (Erleada) or apalutamide plus abiraterone acetate (Zytiga) and prednisone […]
EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk
Patients with lung cancer treated with epidermal growth factor receptor (EGFR) inhibitors may have an increased risk of new-onset keratitis, a U.S. population-based cohort study showed. Over a 20-year period, 1.12% of patients who were treated with EGFR inhibitors developed new-onset keratitis compared with 0.74% of those who did not take these drugs (HR 1.520, […]
Study Assuages Fears of Pancreatic Cancer Risk With GLP-1 Receptor Agonists
Several years after initiating treatment, GLP-1 receptor agonist users didn’t have a pancreatic cancer safety signal, a historical cohort study reported. Compared with basal insulin users, those on a GLP-1 receptor agonist didn’t have a significantly different risk for developing pancreatic cancer in the 5 to 7 years that followed (HR 0.50, 95% CI 0.15-1.71), […]
Clinical Challenges: Beyond CDK4/6 Inhibition in Advanced HR-Positive Breast Cancer
The emergence of CDK4/6 inhibitors has reshaped the therapeutic landscape for advanced hormone receptor (HR)-positive breast cancer, extending progression-free survival (PFS) and in some cases overall survival (OS) when combined with first-line endocrine therapy. Unfortunately, most patients eventually progress, and the next step after CDK4/6 inhibition is perhaps “the hottest topic that all of us […]
Can a GLP-1 Agonist Improve Parkinson’s Symptoms?
An investigational brain-penetrant, pegylated analogue of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) known as NLY01 did not lead to improvement in Parkinson’s disease symptoms compared with placebo, a phase II trial showed. Neither 2.5 mg or 5.0 mg of weekly NLY01 injections showed any difference from placebo in the sum of Movement […]
Is Omitting Radiation Therapy in Low-Risk Breast Cancer a Good IDEA?
SAN ANTONIO — Postmenopausal women with genomically low-risk early hormone receptor (HR)-positive breast cancer had a low risk of recurrence with endocrine therapy alone after lumpectomy, a randomized trial showed. The 5-year overall survival (OS) and cancer-specific survival (CSS) rates were 100% without adjuvant radiation therapy (RT) in 186 women ages 50-69 followed for at […]
‘We’re Not There Yet’: CAR T-Cell Therapy for Renal Cell Carcinoma
NASHVILLE, Tenn. — Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here. CAR T-cell therapy is not yet ready for clinical practice, but enrolling patients in the growing number of clinical trials can help […]
Tebentafusp’s OS Benefit in Uveal Melanoma Holds Up at 3 Years
MADRID — The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated metastatic uveal melanoma, updated results of a phase III trial demonstrated. In HLA-A*02:01-positive patients, landmark analyses showed improved overall survival (OS) at 1, 2, and 3 years with tebentafusp versus […]